<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33127185</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0046</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>218</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Drug and alcohol dependence</Title>
          <ISOAbbreviation>Drug Alcohol Depend</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Drug checking identifies counterfeit alprazolam tablets.</ArticleTitle>
        <Pagination>
          <StartPage>108300</StartPage>
          <MedlinePgn>108300</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drugalcdep.2020.108300</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0376-8716(20)30465-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Non-prescribed benzodiazepine use is increasing in North America, especially among youth. Owing to increasing demand, counterfeit benzodiazepine tablets are mass-produced in clandestine, unregulated environments and sold as legitimate pharmaceuticals. This study aimed to examine the contents of counterfeit alprazolam tablets available in the unregulated drug market in British Columbia, Canada.</AbstractText>
          <AbstractText Label="METHODS">Data were collected from an ongoing evaluation of a community drug checking service in British Columbia between October 2017 and March 2020. The service operates point-of-care in harm reduction sites using Fourier-transform infrared (FTIR) spectrometers coupled with fentanyl and benzodiazepine immunoassay strips. A subset of samples were sent for confirmatory analysis at partner laboratories and underwent one or more of gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, and quantitative nuclear magnetic resonance analysis.</AbstractText>
          <AbstractText Label="RESULTS">During the study period, 10,814 total samples were submitted for drug checking, 139 of which were expected to be Xanax (alprazolam) or generic tablets and met the criteria for inclusion. Using FTIR analysis, 33 (23.7 %) samples were identified to contain alprazolam. Only 122 samples were checked using benzodiazepine immunoassay strips and 88 (72.1 %) tested positive. Qualitative results from the 20 samples submitted for confirmatory analysis included various new psychoactive substances and only 2 contained only alprazolam.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Our findings provide evidence that Xanax tablets obtained from the unregulated drug market are likely to be counterfeit and may not contain alprazolam. Drug checking offers people who use drugs a valuable means to determine the contents of their substances; however, limitations of point-of-care technologies must be considered.</AbstractText>
          <CopyrightInformation>Copyright Â© 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tobias</LastName>
            <ForeName>Samuel</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, British Columbia, V6Z 2A9, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shapiro</LastName>
            <ForeName>Aaron M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Provincial Toxicology Centre, 655 West 12th Ave., Vancouver, British Columbia, V5Z 4R4, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia, V6T 2B5, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grant</LastName>
            <ForeName>Cameron J</ForeName>
            <Initials>CJ</Initials>
            <AffiliationInfo>
              <Affiliation>British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, British Columbia, V6Z 2A9, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priya</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, British Columbia, V6Z 2A9, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lysyshyn</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, British Columbia, V6T 1Z3, Canada; Vancouver Coastal Health Authority, 801-601 West Broadway, Vancouver, British Columbia, V5Z 4C2, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ti</LastName>
            <ForeName>Lianping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, British Columbia, V6Z 2A9, Canada; Department of Medicine, University of British Columbia, 10th Floor-2775 Laurel Street, Vancouver, British Columbia, V5Z 1M9, Canada. Electronic address: bccsu-lt@bccsu.ubc.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Drug Alcohol Depend</MedlineTA>
        <NlmUniqueID>7513587</NlmUniqueID>
        <ISSNLinking>0376-8716</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058110">Counterfeit Drugs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013607">Tablets</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>UF599785JZ</RegistryNumber>
          <NameOfSubstance UI="D005283">Fentanyl</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YU55MQ3IZY</RegistryNumber>
          <NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000525" MajorTopicYN="Y">Alprazolam</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001955" MajorTopicYN="N" Type="Geographic">British Columbia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058110" MajorTopicYN="Y">Counterfeit Drugs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005283" MajorTopicYN="N">Fentanyl</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040261" MajorTopicYN="N">Harm Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Alprazolam</Keyword>
        <Keyword MajorTopicYN="Y">Drug checking</Keyword>
        <Keyword MajorTopicYN="Y">Etizolam</Keyword>
        <Keyword MajorTopicYN="Y">Fentanyl</Keyword>
        <Keyword MajorTopicYN="Y">Harm reduction</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>5</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33127185</ArticleId>
        <ArticleId IdType="doi">10.1016/j.drugalcdep.2020.108300</ArticleId>
        <ArticleId IdType="pii">S0376-8716(20)30465-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
